Developing new cancer drugs is expensive. Before a new cancer drug goes to trial it is developed for a year or two, and costs around $100 million. Also, 95% of cancer drugs fail in clinical trials meaning there are lots of misses before a hit. Berg, a biotech startup, wants to harness artificial intelligence to develop the next generation of cancer treatments. The company has created BPM 31510, the first cancer drug developed by artificial intelligence being tested in clinical studies. When cancer spreads mitochondria that usually tell damaged cells to die go crazy, and spread. BPM 31510 focuses on the mitochondria, and tries to restore a normal cell’s dying process. Though BPM 31510 is still in early trial stages, it could hint at how future drugs will be developed.
The next frontier in medicine: drugs designed by artificial intelligence
More of Today's Solutions
Nepal’s highest court orders government to guarantee same-sex marriage rights
BY THE OPTIMIST DAILY EDITORIAL TEAM Finally, Nepal has marriage equality. On June 18, 2026, the Supreme Court issued a binding directive ordering the ...
Read MoreThe skin compound that makes some more delicious to mosquitoes than others
BY THE OPTIMIST DAILY EDITORIAL TEAM Mosquitoes don’t pick targets randomly. They run a multi-stage sensory scan, and new research is beginning to explain ...
Read More3 healthy habits to boost your immunity this cold and flu season
A mild headache that just won't go away, a box of tissues by the bed, and sleeping uncomfortably with your mouth wide open... It's ...
Read More3 foolproof ways to signal commitment in the confusing world of modern dating
Even while the ceremony and tradition of conventional marriages are losing their appeal to many couples these days, the pursuit of long-term relationships remains a ...
Read More
